GENOME BIOLOGICS UG

Their core work

Genome Biologics is a German biotech SME developing technology to make preclinical pharmaceutical research faster, cheaper, and less reliant on animal testing. Their work targets a core inefficiency in drug development: the preclinical phase before human trials, where costs are high and animal models often fail to predict human outcomes. The progression of their two H2020 projects — from feasibility (SME-1) to full development (SME-2) — shows a company that validated a concept and then scaled it into a fundable product. The explicit inclusion of "ethical burden" in their second project title signals involvement in the 3Rs space (replacement, reduction, refinement of animal use), likely through genomic or in vitro biological models.

What they specialise in

How they've shifted over time

Genome Biologics has a short but coherent H2020 trajectory: a 2017 feasibility study establishing proof-of-concept, followed by a 2018–2021 full development grant worth €2.4M. The shift from the first to the second project title — adding "ethical burden" alongside cost and speed — suggests the technology matured to explicitly address animal testing reduction, which is a growing regulatory and market pressure in European pharma. With no projects after 2021 in this dataset, it is unclear whether they moved to commercial phase or pursued further funding elsewhere.

They appear to be moving toward a commercial product in the animal-testing-alternatives space, having completed the full SME Instrument cycle — the next step would be market entry or Series A funding, not further research grants.

How they like to work

Genome Biologics consistently led both of their H2020 projects as sole coordinator — a pattern typical of companies using the SME Instrument, which is designed for single-company innovation funding rather than consortium research. This means they have no recorded consortium partners in the H2020 data, which is expected given the funding scheme, not a sign of isolation. Anyone wishing to collaborate with them would likely be engaging as a client, pilot partner, or co-development partner rather than a traditional consortium member.

Within H2020, Genome Biologics operated as a solo entity on both grants — zero recorded consortium partners and zero international collaborations in the dataset. This is structurally expected for SME Instrument recipients and does not preclude industry partnerships or customer relationships outside the EU grant system.

What sets them apart

Genome Biologics is one of the rare German biotech SMEs to have successfully completed the full SME Instrument cycle — Phase 1 feasibility through Phase 2 development — in the preclinical tools space. Their specific angle of combining cost reduction with ethical (animal testing) burden reduction places them at the intersection of pharma efficiency and the EU's growing regulatory push for non-animal methods. For a pharma company or CRO looking for a tool provider with EU-validated technology and a development track record, this is a small but focused team worth investigating.

Highlights from their portfolio

• GENBIO
  A €2.4M SME Phase 2 award — one of the larger single-company grants available — confirming independent expert validation of both the technology and the market case for reducing preclinical research cost and animal use.
• Genome Biologics
  The SME Phase 1 feasibility project that launched the company's EU funding track; its success directly enabled the larger GENBIO award one year later.